Overview

A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Ramosetron